Abstract
The review summarizes the chemistry of the third generation of photosensitizers, namely, the derivatives of natural bacteriochlorophyll a for photodynamic treatment of cancer. The compounds of this class strongly absorb light at λ=770-850 nm. This unique property opens new therapeutic opportunities due to deeper tissue penetration of light, thereby increasing the photodamage for tumor eradication. Analyzed are the modifications of bacteriochlorophyll a that improve physico-chemical characteristics of compounds and enhance accumulation in tumors. Focusing on the delivery of photosensitizers to the tumor site and to specific intracellular compartments, we describe the conjugates of bacteriochlorophyll a derivatives with carbohydrate and protein carriers. Boronated bacteriochlorins can be used in both photodynamic and boron neutron capture therapy.
Keywords: Cancer Therapy, Bacteriochlorophyll a, photosensitizers, photodynamic treatment, tumor eradication, boron neutron capture therapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Bacteriochlorophyll a and Its Derivatives: Chemistry and Perspectives for Cancer Therapy
Volume: 8 Issue: 6
Author(s): Mikhail A. Grin, Andrey F. Mironov and Alexander A. Shtil
Affiliation:
Keywords: Cancer Therapy, Bacteriochlorophyll a, photosensitizers, photodynamic treatment, tumor eradication, boron neutron capture therapy
Abstract: The review summarizes the chemistry of the third generation of photosensitizers, namely, the derivatives of natural bacteriochlorophyll a for photodynamic treatment of cancer. The compounds of this class strongly absorb light at λ=770-850 nm. This unique property opens new therapeutic opportunities due to deeper tissue penetration of light, thereby increasing the photodamage for tumor eradication. Analyzed are the modifications of bacteriochlorophyll a that improve physico-chemical characteristics of compounds and enhance accumulation in tumors. Focusing on the delivery of photosensitizers to the tumor site and to specific intracellular compartments, we describe the conjugates of bacteriochlorophyll a derivatives with carbohydrate and protein carriers. Boronated bacteriochlorins can be used in both photodynamic and boron neutron capture therapy.
Export Options
About this article
Cite this article as:
Grin A. Mikhail, Mironov F. Andrey and Shtil A. Alexander, Bacteriochlorophyll a and Its Derivatives: Chemistry and Perspectives for Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (6) . https://dx.doi.org/10.2174/187152008785133128
DOI https://dx.doi.org/10.2174/187152008785133128 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Evidence for the Involvement of Lamins in Aging
Current Aging Science Potential Therapeutic Drugs and Methods for the Treatment of Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Assessment of Bishosphonate Activity In Vitro
Current Pharmaceutical Design Proteasomes as Drug Targets
Current Drug Targets Substance P and its Inhibition in Ocular Inflammation
Current Drug Targets Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) Editorial (Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology)
Current Pharmacogenomics and Personalized Medicine Novel and Emerging Drugs for Acute Myeloid Leukemia: Pharmacology and Therapeutic Activity
Current Medicinal Chemistry PI3K-Akt Signaling and Viral Infection
Recent Patents on Biotechnology Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Regeneration of Pancreatic β-Cells in vivo as a Potential Therapeutic Approach for Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression
Current Drug Targets Simultaneous Interruption of Signal Transduction and Cell Cycle Regulatory Pathways: Implications for New Approaches to the Treatment of Childhood Leukemias
Current Drug Targets Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets